Literatur zur Pleurodese

  • Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer 33 (4): 916-22, 1974.
  • Andrews CO, Gora ML. Pleural effusions: pathophysiology and management. Ann Pharmacother 28 (7-8): 894-903, 1994.
  • Antony VB, Mohammed KA. Pathophysiology of pleural space infections. Semin Respir Infect 14 (1): 9-17, 1999.
  • Austgen M. [Palliative therapy of tumor-induced pleural effusions with radioisotopes]. Pneumologie 43 (2): 88-91, 1989.
  • Belani CP, Pajeau TS, Bennett CL. Treating malignant pleural effusions cost consciously. Chest 113 (1 Suppl): 78S-85S, 1998.
  • Bjermer L, Gruber A, Sue-Chu M, Sandstrom T, Eksborg S, Henriksson R. Effects of intrapleural mitoxantrone and mepacrine on malignant pleural effusion--a randomised study. Eur J Cancer 31A (13-14): 2203-8, 1995.
  • Böck D. Neue zytomorphologische Ergebnisse bei lokaler Behandlung des karzinomatösen Pleuraergusses. Krebsgeschehen (2): 33-34, 1983.
  • Böck D, Salzer G. Iscadorbehandlung maligner Pleuraergüsse. Cytologische Befunde und klinische Ergebnisse. In: Wolff, ed. Die Mistel in der Krebsbehandlung. Frankfurt: Vittorio Klostermann Verlag, pp. 123-135, 1985.
  • Böck D, Salzer G. Morphologischer Nachweis einer Wirksamkeit der Iscadorbehandlung maligner Pleuraergüsse und Ihre klinischen Ergebnisse. Krebsgeschehen 12 (3): 49-53, 1980.
  • Böck P. Lokalbehandlung der Pleurakarzinose: Elektronenmikroskopische Befunde. Krebsgeschehen (2): 35-39, 1983.
  • Bolcskei PL, Gill E, Haberstumpf H, Lessnau KD, Wellhofer G. [Pleurodesis using an acrylate glue in the treatment of therapy- resistant symptomatic pneumothorax]. Pneumologie 44 Suppl 1: 293-4, 1990.
  • Cariati A, Taviani M, Pescio G, Cesaro S, Cariati P, Conti F, Cariati E. Management of thoracic duct complex lesions (chylothorax): experience in 16 patients. Lymphology 29 (2): 83-6, 1996.
  • DeCamp MM, Jr., Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest 112 (4 Suppl): 291S-295S, 1997.
  • Deppermann K, Kreuser E. Therapie maligner Pleuraergüsse. In: Schmoll, Höffken, Possinger, eds. Kompendium internistische Onkolgie. 2. Auflage ed: Springer Verlag, pp. 1852-64, 1996.
  • Fentiman IS, Rubens RD, Hayward JL. A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Eur J Cancer Clin Oncol 22 (9): 1079-81, 1986.
  • Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg 170 (1): 69-74, 1995.
  • Frank W, Grosser H, Mai J, Loddenkemper R. [Pleurodesis with tetracycline hydrochloride]. Pneumologie 43 (2): 80-4, 1989.
  • Furrer M, Inderbitzi R. [Pleurodesis technique in malignant pleural effusion]. Schweiz Med Wochenschr 122 (6): 181-8, 1992.
  • Girke M, Kröz M, Matthes B. Maligner Pleuraerguß bei Verdacht auf Bronchial-Carcinom, komplette Remission. Der Merkurstab 51 (1): 25-30, 1998.
  • Gjomarkaj M, Pace E, Melis M, Spatafora M, Toews GB. Mononuclear cells in exudative malignant pleural effusions. Characterization of pleural phagocytic cells. Chest 106 (4): 1042-9, 1994.
  • Grossi F, Pennucci MC, Tixi L, Cafferata MA, Ardizzoni A. Management of malignant pleural effusions. Drugs 55 (1): 47-58, 1998.
  • Groth G, Gatzemeier U, Haussingen K, Heckmayr M, Magnussen H, Neuhauss R, Pavel JV. Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 2 (3): 213-5, 1991.
  • Guerin JC, Boniface E. [Pleurodesis technics]. Rev Prat 40 (20): 1854-6, 1990.
  • Gust R, Fabel H. [Fibrin glue pleurodesis in recurrent malignant pleural effusions]. Pneumologie 43 (2): 85-7, 1989.
  • Gust R, Kleine P, Fabel H. [Fibrin glue and tetracycline pleurodesis in recurrent malignant pleural effusions. A randomized comparative study]. Med Klin 85 (1): 18-23, 1990.
  • Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12 (1): 54-75, 1985.
  • Heckmayr M, Gatzemeier U, Neuhauss R, von Pawel J, Häußlinger K. Mitoxantron in der likalen Therapie maligner Pleuraergüsse. Beiträge zur Onkologie 33: 75-80, 1988.
  • Hentrich M, Hartenstein R. [Treatment of malignant effusions in body cavities]. Internist (Berl) 38 (8): 794-804, 1997.
  • Hentrich M, Hartenstein R. [Treatment of malignant effusions in body cavities]. Internist (Berl) 38 (8): 794-804, 1997.
  • Hillerdal G. Chylothorax and pseudochylothorax. Eur Respir J 10 (5): 1157-62, 1997.
  • Izbicki R, Weyhing BTd, Baker L, Caoili EM, Vaitkevicius VK. Pleural effusion in cancer patients. A prospective randomized study of pleural drainage with the addition of radioactive phsophorous to the pleural space vs. pleural drainage alone. Cancer 36 (4): 1511-8, 1975.
  • Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 56 (4): 905-9, 1985.
  • Kessinger A, Wigton RS. Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: a randomized study. J Surg Oncol 36 (2): 81-3, 1987.
  • Kim M, Park Y, Lee S, Kim S, Lee S, Kim C, Kim Y, Kim K, Moon H, Song J, Park S. Comparative Study on the Effects of a Viscum album (L.) Extract (Mistletoe) and Doxycycline for Pleurodesis in Patients with Malignant Pleural Effusion. Korean Journal of Medicine 57 (Suppl. II): 121-, 1999.
  • Kimura S, Sone S, Takahashi K, Uyama T, Ogura T, Monden Y. Antitumour potential of pleural cavity macrophages in lung cancer patients without malignant effusion. Br J Cancer 59 (4): 535-9, 1989.
  • Kokron O. [Local therapy of metastatic pleural effusions with zusammenfassung proteolytic enzymes (author's transl)]. Osterr Kneipp Mag 4 (4): 82-5, 1977.
  • Kreuser ED. [Malignant pleural effusions. Pathophysiology, diagnosis and therapy]. Dtsch Med Wochenschr 110 (36): 1381-6, 1985.
  • Kreuser ED, Seifried E, Harsch U, Brass B, Schreml W, Heimpel H. [Fibrin pleurodesis in malignant pleural effusions]. Dtsch Med Wochenschr 110 (36): 1365-8, 1985.
  • Kroegel C, Antony VB. Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy. Eur Respir J 10 (10): 2411-8, 1997.
  • Kropp R, Loddenkemper R. [Recurring, menstruation-dependent spontaneous pneumothorax--successful treatment with chemical pleurodesis]. Prax Klin Pneumol 39 (6): 208-9, 1985.
  • Light RW, Macgregor MI, Luchsinger PC, Ball WC, Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 77 (4): 507-13, 1972.
  • Light RW, Vargas FS. Pleural sclerosis for the treatment of pneumothorax and pleural effusion. Lung 175 (4): 213-23, 1997.
  • Liu G, Crump M, Goss PE, Dancey J, Shepherd FA. Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 14 (12): 3141-7, 1996.
  • Loddenkemper R. [The diagnosis of pleural effusions]. Dtsch Med Wochenschr 117 (39): 1487-91, 1992.
  • Loddenkemper R, Frank W. [The therapy of pleural effusions]. Dtsch Med Wochenschr 117 (40): 1527-31, 1992.
  • Lynch TJ, Jr. Management of malignant pleural effusions. Chest 103 (4 Suppl): 385S-389S, 1993.
  • Mack MJ, Landreneau RJ, Hazelrigg SR, Acuff TE. Video thoracoscopic management of benign and malignant pericardial effusions. Chest 103 (4 Suppl): 390S-393S, 1993.
  • Maiche AG, Virkkunen P, Kontkanen T, Moykkynen K, Porkka K. Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. A comparative study. Am J Clin Oncol 16 (1): 50-3, 1993.
  • Miles DW, Knight RK. Diagnosis and management of malignant pleural effusion. Cancer Treat Rev 19 (2): 151-68, 1993.
  • Moffett MJ, Ruckdeschel JC. Bleomycin and tetracycline in malignant pleural effusions: a review. Semin Oncol 19 (2 Suppl 5): 59-62; discussion 62-3, 1992.
  • Moores DW. Malignant pleural effusion. Semin Oncol 18 (1 Suppl 2): 59-61, 1991.
  • Müller H. Aus der Praxis: Iscador-Instillation bei Ergüssen in Körperhöhlen. Krebsgeschehen 15 (2): 59-60, 1983.
  • Musch E, Paar W, Hoffmann B, Seitzer D, Chemaissani A, Bode U, Peiss J, Mackes K, Hartlapp H, Eberhard K. Intrpleurale Instillation von Mitoxantron zur Palliativ-Therapie maligner Pleuraergüsse. Tumor Diagnostik und Therapie 10: 64-71, 1989.
  • Ortlieb H, Schildge J, Cegla M. [Treatment of malignant pleural effusions by parietal pleurectomy]. Helv Chir Acta 54 (3): 325-8, 1987.
  • Ostrowski MJ. Intracavitary therapy with bleomycin for the treatment of malignant pleural effusions. J Surg Oncol Suppl 1: 7-13, 1989.
  • Ostrowski MJ, Priestman TJ, Houston RF, Martin WM. A randomized trial of intracavitary bleomycin and Corynebacterium parvum in the control of malignant pleural effusions. Radiother Oncol 14 (1): 19-26, 1989.
  • Paladine W, Cunningham TJ, Sponzo R, Donavan M, Olson K, Horton J. Intracavitary bleomycin in the management of malignant effusions. Cancer 38 (5): 1903-8, 1976.
  • Patel MC, Flower CD. Radiology in the management of pleural disease. Eur Radiol 7 (9): 1454-62, 1997.
  • Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J 10 (7): 1648-54, 1997.
  • Rossi GA, Felletti R, Balbi B, Sacco O, Cosulich E, Risso A, Melioli G, Ravazzoni C. Symptomatic treatment of recurrent malignant pleural effusions with intrapleurally administered Corynebacterium parvum. Clinical response is not associated with evidence of enhancement of local cellular- mediated immunity. Am Rev Respir Dis 135 (4): 885-90, 1987.
  • Ruckdeschel JC, Moores D, Lee JY, Einhorn LH, Mandelbaum I, Koeller J, Weiss GR, Losada M, Keller JH. Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline [published erratum appears in Chest 1993 May;103(5):1640] [see comments]. Chest 100 (6): 1528-35, 1991.
  • Sahn SA. Pleural diseases related to metastatic malignancies [see comments]. Eur Respir J 10 (8): 1907-13, 1997.
  • Sahn SA. State of the art. The pleura. Am Rev Respir Dis 138 (1): 184-234, 1988.
  • Salzer G. [The local treatment of malignant pleural exudations with Iscador (a drug obtained from Misteltoe). Preliminary report (author's transl)]. Osterr Kneipp Mag 4 (1): 13-4, 1977.
  • Salzer G. Lokalbehandlung der Pleurakarzinose. Krebsgeschehen (2): 52-53, 1983.
  • Salzer G. Pleura carcinosis. Cytomorphological findings with the mistletoe preparation iscador and other pharmaceuticals. Oncology 43 Suppl 1: 66-70, 1986.
  • Salzer G, Muller H. [Topical treatment of malignant pleural effusions with iscador, a mistletoe preparation (author's transl)]. Prax Klin Pneumol 32 (11): 721-9, 1978.
  • Salzer G, Popp W. Die lokale Iscadorbehandlung der Pleurakarzinose. In: Jungi, Senn, eds. Krebs und Alternativmedizin. Berlin-Heidelberg: Springer-Verlag, pp. 70-83, 1990.
  • Schafers SJ, Dresler CM. Update on talc, bleomycin, and the tetracyclines in the treatment of malignant pleural effusions. Pharmacotherapy 15 (2): 228-35, 1995.
  • Schlodder D. Vorteile von Mistelpräparaten. Dt. Ärztebl. 85 (27): 1193, 1988.
  • Schmidt M. Therapie maligner Pleuraergüsse. In: Seeber, Schütte, eds. Therapiekonzepte Onkologie. 3. Auflage ed: Springer Verlag, pp. 1355-63, 1998.
  • Schmidt M, Schaarschmidt G, Chemaissani A. [Pleurodesis in malignant pleural effusion: bleomycin vs. mitoxantrone]. Pneumologie 51 (4): 367-72, 1997.
  • Sedlarik KM, Kirsten D, Durschmied H, Strauss B. [Pleurodesis with electrically activated autologous blood in recurrent pleural effusion--preliminary report]. Z Arztl Fortbild (Jena) 85 (19): 943-4, 1991.
  • Sherman S, Grady KJ, Seidman JC. Clinical experience with tetracycline pleurodesis of malignant pleural effusions. South Med J 80 (6): 716-9, 1987.
  • Siegel RD, Schiffman FJ. Systemic toxicity following intracavitary administration of bleomycin. Chest 98 (2): 507, 1990.
  • Strange C, Tomlinson JR, Wilson C, Harley R, Miller KS, Sahn SA. The histology of experimental pleural injury with tetracycline, empyema, and carrageenan. Exp Mol Pathol 51 (3): 205-19, 1989.
  • Stumpf C, Büssing A. Stimulation of antitumour immunity by intrapleural instillation of a Viscum album L. ectract. Anti Cancer Drugs 8 (Suppl 1): S23-S26, 1997.
  • Stumpf C, Schietzel M. Intrapleurale Instillation eines Extraktes aus Viscum album L. zur Behandlung maligner Pleuraergüsse. Tumor Diagnostik & Therapie 15 (2): 56-62, 1994.
  • Takahashi K, Sone S, Kimura S, Ogura T, Monden Y. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion. Chest 103 (6): 1732-8, 1993.
  • Tattersall M. Pleural effusions. Curr Opin Oncol 4 (4): 642-6, 1992.
  • Torsten U, Opri F, Weitzel H. Local therapy of malignant pleural effusion with mitoxantrone [see comments]. Anticancer Drugs 3 (1): 17-8, 1992.
  • Turler A, Walter M, Schmitz-Rixen T. [Current treatment strategy in malignant pleural effusion]. Wien Klin Wochenschr 108 (9): 255-61, 1996.
  • Ullmer E, Wyser C, Soler M. [Pleural effusion: what next?]. Schweiz Med Wochenschr 128 (12): 451-8, 1998.
  • Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases [see comments]. Chest 110 (6): 1387-93, 1996.
  • Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions [see comments]. Ann Intern Med 120 (1): 56-64, 1994.
  • Walter M, Turler A, Schmitz-Rixen T. [Talc pleurodesis in recurrent malignant pleural effusion--a prospective follow-up study]. Zentralbl Chir 121 (3): 216-22, 1996.
  • Weissberg D, Ben-Zeev I. Talc pleurodesis. Experience with 360 patients. J Thorac Cardiovasc Surg 106 (4): 689-95, 1993.
  • WHO. WHO Handbook of reporting results of cancer treatment, 1979.
  • Wong JW, Pitlik D, Abdul-Karim FW. Cytology of pleural, peritoneal and pericardial fluids in children. A 40-year summary. Acta Cytol 41 (2): 467-73, 1997.
  • Zaloznik AJ, Oswald SG, Langin M. Intrapleural tetracycline in malignant pleural effusions. A randomized study. Cancer 51 (4): 752-5, 1983.

[zurück zur Mistelpleurodese]